Cannabinoids: Occurrence and medicinal chemistry

Current Medicinal Chemistry

Volumn 18, Issue 7, 2011, Pages 1085-1099

  Appendino, G ^a   Chianese, G ^b   Taglialatela Scafati, O ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

9 tetrahydrocannabinol; Cannabinoids; Cannabis sativa L.; Endocannabinoids; Pain treatment; Psychotropic effects; Structure activity relationships

Indexed keywords

ANANDAMIDE; CANNABICHROMANONE; CANNABICHROMENE; CANNABICITRAN; CANNABICOUMARONONE; CANNABICYCLOL; CANNABIDIOL; CANNABIDIOLIC ACID; CANNABIELSOIN; CANNABIGEROL; CANNABIMOVONE; CANNABINEROLIC ACID; CANNABINODIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOL; CANNABINOLIC ACID; CANNABIRIPSOL; CANNABIS; CANNABITETROL; CANNABITRIOL; CARMAGEROL; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; ISOTETRAHYDROCANNABINOL; NABILONE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOGENESIS; DEPRESSION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG ADENOCARCINOMA; NEUROPROTECTION; NONHUMAN; PAIN; PHYTOCHEMISTRY; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PSYCHOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CANNABINOIDS; CANNABIS; CHEMISTRY, PHARMACEUTICAL; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952784020     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794940888     Document Type: Article

References (129)

1. Hillig, K.W. Genetic evidence for separation in Cannabis (Cannabaceae). Genet. Resour. Crop. Evol., 2005, 52, 161-180. (Pubitemid 40580346)
2. Keller, A.; Leupin, M.; Mediavilla, V.; Wintermantel, E. Influence of the growth stage of industrial hemp on chemical and physical properties of the fibres. Ind. Crops Prod., 2001, 13, 35-48. (Pubitemid 32247434)
3. Huestis, M.A.; Henningfield, J.E.; Cone, E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THC-COOH during and after smoking marijuana. J. Anal. Toxicol., 1992, 16, 276-282.
4. Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. J. Clin. Pharmacol., 1981, 21, 57S-59S.
5. 9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2. Eur. Neuropsychopharm., 2010, 20, 622-631.
6. de Lago, E.; Gomez-Ruiz, M.; Moreno-Martet, M.; Fernandez-Ruiz, J. Cannabinoids, multiple sclerosis and neuroprotection. Exp. Rev. Clin. Pharmacol., 2009, 2, 645-660.
7. 9- tetrahydrocannabinol and aqueous dynamics in glaucoma. J. Clin. Pharmacol., 1981, 21, 467-71.
8. 9- tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur. Arch. Psychiatr. Clin. Neurosci., 1990, 240, 1-4. (Pubitemid 20323888)
9. Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Nonpsychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci., 2009, 30, 515-527.
10. Gertsch, J.; Pertwee, R. G.; Di Marzo, V. Phytocannabinoids beyond the Cannabis plant - do they exist? Br. J. Pharmacol., 2010, 160, 523-529.
11. Di Marzo, V.; De Petrocellis, L. Plant, synthetic, and endogenous cannabinoids in medicine. Ann. Rev. Med., 2006, 57, 553-574. (Pubitemid 43262007)
12. Russo, E.B.; Jiang, H.-E.; Li, X.; Sutton, A.; Carboni, A.; del Bianco, F.; Mandolino, G.; Potter, D.J.; Zhao, Y.-X.; Bera, S.; Zhang, Y.-B.; Lu, E.G.; Ferguson, D.K.; Hueber, F.; Zhao, L.C.; Liu, C.-J., Wang, Y.-F.; Li, C.-S. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J. Exp. Bot., 2008, 59, 4171-4182.
13. Russo, E.B. History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chem. Biodiv., 2007, 4, 1614-1648. (Pubitemid 47381191)
14. Green J. Cannabis Thunder's Mouth Press: New York, 2001.
15. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 1964, 86, 1646-1647.
16. Howlett, A.C.; Johnson, M.R.; Melvin, L.S.; Milne, G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol. Pharmacol., 1988, 33, 297-302. (Pubitemid 18098593)
17. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949. (Pubitemid 23026736)
18. Lawrence, O.; Gostin, J.D. Medical marijuana, American federalism, and the Supreme Court. J. Am. Med. Assoc., 2005, 294, 842-844.
19. Turner, C.E.; Elsohly, M.A.; Boeren, E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod., 1980, 43, 169-234. (Pubitemid 10020139)
20. Elsholy, M.A.; Slade, D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci., 2005, 78, 539-548. (Pubitemid 41653504)
21. Flores-Sanchez, I.J.; Verpoorte, R. Secondary metabolism in cannabis. Phytochem. Rev., 2008, 7, 615-639.
22. Fellermeier, M.; Zenk, M.H. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Lett., 1998, 427, 283-285. (Pubitemid 28225075)
23. Shoyama, Y.; Hirano, H.; Oda, M.; Somehara, T.; Nishioka, I. Cannabis. IX. Cannabichromevarin and cannabigerovarin, two new propyl homologs of cannabichromene and cannabigerol. Chem. Pharm. Bull., 1975, 23, 1894-5.
24. Taura, F.; Morimoto, S.; Shoyama, Y. Cannabinerolic acid, a cannabinoid from Cannabis sativa. Phytochemistry, 1995, 39, 457-8.
25. Appendino, G.; Giana, A.; Gibbons, S.; Maffei, M.; Gnavi, G.; Grassi, G.; Sterner, O. A. Polar Cannabinoid from Cannabis sativa var. Carma. Nat. Prod. Commun., 2008, 3, 1977-1980.
26. Radwan M.M.; ElSohly, M.A.; Slade, D.; Ahmed, S.A.; Khan, I.A.; Ross, S.A. Biologically Active cannabinoids from high-potency Cannabis sativa. J. Nat. Prod., 2009, 72, 906-911.
27. Gaoni, Y.; Mechoulam, R. Cannabichromene, a new active principle in hashish. Chem. Commun., 1966, 20-21.
28. Claussen, U.; von Spulak, F.; Korte, F. Haschish XIV. Zur Kenntnis der inhaltsstoffe des haschish. Tetrahedron, 1968, 24, 1021-1050.
29. Taura, F.; Morimoto, S.; Shoyama, Y. Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid. J. Biol. Chem.,1996, 271, 17411-17416. (Pubitemid 26244305)
30. Lousberg, R.J.J.C.; Bercht, C.A.L.; Van Ooyen, R.; Spronck, H.J.W. Cannabinodiol: Conclusive identification and synthesis of a new cannabinoid from Cannabis sativa. Phytochemistry, 1977, 16, 595-7.
31. Shani, A.; Mechoulam, R. Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron, 1974, 30, 2437-46.
32. Yamamoto, I.; Gohda, H.; Narimatsu, S.; Watanabe, K.; Yoshimura, H. Cannabielsoin as a new metabolite of cannabidiol in mammals. Pharmacol. Biochem. Behav., 1991, 40, 541-546.
33. Friedrich-Fiechtl, J.; Spiteller, G. New cannabinoids. I. Tetrahedron, 1975, 31, 479-87.
34. Taglialatela-Scafati, O.; Pagani, A; Scala, F; De Petrocellis, L; Di Marzo, V.; Grassi, G; Appendino, G. Cannabimovone, a cannabinoid with a rearranged terpenoid skeleton from hemp. Eur. J. Org. Chem., 2010, 11, 2067-2072.
35. Taura, F.; Morimoto, S.; Shoyama, Y.; Mechoulam, R. First direct evidence for the mechanism of δ1-tetrahydrocannabinolic acid biosynthesis. J. Am. Chem. Soc., 1995, 117, 9766-9767.
36. Boeren, E.G.; Elsohly, M.A.; Turner, C.E. Cannabiripsol: A novel Cannabis constituent. Experientia, 1979, 35, 1278-1279. (Pubitemid 10231764)
37. Chan, W.R.; Magnus, K.E.; Watson, H.A. The structure of cannabitriol. Experientia, 1976, 32, 283-284.
38. Elsohly, M.A.; Boeren, E.G.; Turner, C.E. 9,10-Dihydroxy-6a(10a)- tetrahydrocannabinol and 8,9-dihydroxy-6a(10a)-tetrahydrocannabinol: 2 new cannabinoids from Cannabis sativa L. Experientia, 1978, 34, 1127-1128. (Pubitemid 9012992)
39. Ross, S.A.; ElSohly, M.A.; Sultana, G.N.N.; Mehmedic, Z.; Hossain, C.F.; Chandra, S. Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochem. Anal., 2005, 16, 45-48.
40. Bercht, C.A.L.;. Lousberg, R.J.J., Küppers, F.J.E.M.; Salemink, C.A. Cannabicitran: A new naturally occurring tetracyclic diether from Lebanese Cannabis sativa. Phytochemistry, 1974, 13, 619-621.
41. Gaoni, Y.; Mechoulam, R. Hashish. XIV. Isotetrahydrocannabinols. Isr. J. Chem., 1968, 6, 679-690.
42. Braemer, R.; Paris, M. Biotransformation of cannabinoids by cell suspension culture of Cannabis sativa L. Plant Cell. Rep., 1987, 6, 150-152.
43. Ahmed, S.A.; Ross, S.A.; Slade, D.; Radwan, M.M.; Khan, I.A.; ElSohly, M.A. Structure determination and absolute configuration of cannabichromanone derivatives from high potency Cannabis sativa. Tetrahedron Lett., 2008, 49, 6050-6053.
44. Woelkart, K.; Salo-Ahen, O.M.H.; Bauer, R. CB receptor ligands from plants. Curr. Top. Med. Chem., 2008, 8, 173-186. (Pubitemid 351795768)
45. Bohlmann, F.; Hoffmann, E. Cannabigerol-ahnliche verbindungen aus Helichrysum umbraculigerum (Paper in German). Phytochemistry, 1979, 18, 1371-1374.
46. Crombie, L.W., Crombie, W.M.L.; Firth, D.F. Synthesis of bibenzyl cannabinoids, hybrids of two biogenetic series found in Cannabis sativa. J. Chem. Soc. Perkin Trans. I, 1988, 1263-1270.
47. Toyota, M.; Shimamura, T.; Hishii, H.; Renner, M.; Braggings, J.; Asakawa, Y. New Bibenzyl Cannabinoid from the New Zealand Liverwort Radula marginata. Chem. Pharm. Bull., 2002, 50, 1390-1392. (Pubitemid 41702045)
48. Razdan, R.K.; Dalzell, H.C.; Handrick, G.R. Hashish. X. Simple one-step synthesis of (-)-δ1-tetrahydrocannabinol (THC) from p-mentha-2,8-dien-1-ol and olivetol. J. Am. Chem. Soc., 1974, 96, 5860-5865.
49. Rinaldi-Carmona, M.; Pialot, F.; Congy, C.; Redon, E.; Barth, F.; Bachy, A.; Brelière, J.C.; Soubrié, P.; Le Fur, G. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci., 1996, 58, 1239-1247. (Pubitemid 26096331)
50. Devane, W.A.; Dysarz III, F.A.; Johnson, M.R.; Melvin, L.S.; Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol., 1988, 34, 605-613. (Pubitemid 19007296)
51. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 1932-1936.
52. Xie, X.-Q.; Chen, J.-Z.; Billings, E.M. 3D structural model of the G-proteincoupled cannabinoid CB2 receptor. Protein Struct. Funct.Genet., 2003, 53, 307-319. (Pubitemid 37193825)
53. Jarai, Z.; Wagner, J.A.; Varga, K.; Lake, K.D.; Compton, D.R.; Martin, B.R.; Zimmer, A.M.; Bonner, T.I.; Buckley, N.E.; Mezey, E.; Razdan, R.K.; Zimmer, A.; Kunos, G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 14136-14141.
54. Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.H.; George, S. R.; Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res., 1999, 64, 193-198. (Pubitemid 29052470)
55. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R.A.; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 16511-16516.
56. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R.A.; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 16511-16516.
57. Cooper, Z.D.; Haney, M. Cannabis reinforcement and dependence: Role of the cannabinoid CB1 receptor. Addiction Biol., 2008, 13, 188-195. (Pubitemid 351698888)
58. Huffman, J.W. CB2 receptor ligands. Mini Rev. Med. Chem., 2005, 5, 641-649.
59. Burstein, S. The cannabinoids acids: Nonpsychoactive derivatives with therapeutic potential. Pharmacol. Ther., 1999, 82, 87-96. (Pubitemid 29134981)
60. Thomas, A.; Baillie, G.L.; Phillips, A.M.; Razdan, R.K.; Ross, R.A.; Pertwee, R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol., 2007, 150, 613-623. (Pubitemid 46355558)
61. 9- tetrahydrocannabivarin in mice in vivo. Br. J. Pharmacol., 2007, 150, 586-594. (Pubitemid 46355554)
62. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232, 54-61.
63. Bab, I.; Ofek, O.; Tam, J.; Rehnelt, J.; Zimmer, A. Endocannabinoids and the regulation of bone metabolism. J. Neuroendocrinol., 2008, 20, 69-74. (Pubitemid 351552679)
64. Matias, I.; Gonthier, M.P.; Orlando, P.; Martiadis, V.; De Petrocellis, L.; Cervino, C.; Petrosino, S.; Hoareau, L.; Festy, F.; Pasquali, R.; Roche, R.; Maj, M.; Pagotto, U.; Monteleone, P.; Di Marzo, V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and betapancreatic cells and in obesity and hyperglicemia. J. Clin. Endocrinol. Metab., 2006, 91, 3171-3180. (Pubitemid 44271774)
65. Akopian A.A.; Ruparel, N.B.; Jeske, N.A.; Patwardhan, A.; Hargreaves, K.M. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trend Pharmacol. Sci., 2009, 30, 79-84.
66. Zarrindast, M.-R.; Kangarlu-Haghighi, K.; Khalilzadeh, A.; Fazli-Tabaei, S. Influence of intracerebroventricular administration of cannabinergic drugs on morphine state-dependent memory in the step-down passive avoidance test. Behav. Pharmacol., 2006, 17, 231-237.
67. Fernandez-Ruiz, J.; Gonzalez, S. Cannabinoid control of motor function at the basal ganglia. Handb. Exp. Pharmacol., 2005, 168, 479-507.
68. Coutts, A.A.; Izzo, A.A. The gastrointestinal pharmacology of cannabinoids: An update. Curr. Opin. Pharmacol., 2004, 4, 572-579. (Pubitemid 40267871)
69. Di Carlo, G.; Izzo, A.A. Cannabinoids for gastrointestinal diseases: Potential therapeutic applications. Expert Opin. Investig. Drugs, 2003, 12, 39-49. (Pubitemid 36104642)
70. Mao, J.; Price, D.D.; Lu, J.; Keniston, L.; Mayer, D. J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett., 2000, 280, 13-16. (Pubitemid 30069562)
71. Mechoulam, R.; Ben-Shabat, S.; Hanuš, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50, 83-90.
72. Porter, A.C.; Sauer, J.-M.; Knierman, M.D.; Becker, G.W.; Berna, M. J.; Bao, J.; Nomikos, G. G.; Carter, P.; Bymaster, F.P.; Leese, A.B.; Felder, C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301, 1020-1024. (Pubitemid 34595094)
73. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide , has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB1, TRPV1 and PPAR-gamma receptors and neurotrophic factors. Pain, 2008, 139, 541-550.
74. Godlewski, G.; Offertaler, L.; Wagner, J.A.; Kunos, G. Receptors for acylethanolamides- GPR55 and GPR119. Prostag. Lipid Mediat., 2009, 89, 105-111.
75. Garcia, M.C.; Adler-Graschinsky, E.; Celuch, S.M. Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur. J. Pharmacol., 2009, 610, 75-80.
76. Appendino, G.; Ligresti, A.; Minassi, A.; Cascio, M.G.; Allarà, M.; Taglialatela-Scafati, O.; Pertwee, R.G.; De Petrocellis, L.; Di Marzo, V. Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J. Med. Chem., 2009, 52, 3001-3009.
77. Shim, J.Y.; Welsh, W.J.; Howlett, A.C. Homology model of the CB1 cannabinoid receptor: Sites critical for non-classical cannabinoid agonist interaction. Biopolymers, 2003, 71, 169-189. (Pubitemid 36702318)
78. Govaerts, S.; Hermans, E.; Lambert, D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci., 2004, 23, 233-243. (Pubitemid 39369878)
79. Razdan, R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev., 1986, 38, 75-149. (Pubitemid 16001328)
80. 8-THC isomers: Exceptionally potent cannabinoids. Bioorg. Med. Chem. Lett., 1997, 7, 2799-2804. (Pubitemid 27472831)
81. Papahatjis, D.P.; Nikas, S.P.; Kourouli, T.; Chari, R.; Xu, W.; Pertwee, R.G.; Makriyannis, A. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J. Med. Chem., 2003, 46, 3221-3229. (Pubitemid 36842408)
82. 2) selective ligands. W.O. Patent 01/28329, April 2001.
83. 2 receptors. Mol. Pharmacol., 1999, 56, 1362-1369.
84. Frank, B.; Serpell, M. G.; Hughes, J.; Matthews, J.N.S.; Kapur, D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. Br. Med. J., 2008, 336, 199-201. (Pubitemid 351212676)
85. Jourdan, T.; Djaouti, L.; Demizieux, L.; Gresti, J.; Verges, B.; Degrace, P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes, 2010, 59, 926-934.
86. Colombo, G.; Orru, A.; Lai, P.; Cabras, C.; Maccioni, P.; Rubio, M.; Gessa, G. L.; Carai, M.A. M. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: Preclinical evidence. Mol. Neurobiol., 2007, 36, 102-112. (Pubitemid 351360349)
87. Mackie, K. From active ingredients to the discovery of the targets: The cannabinoid receptors. Chem. Biodiv., 2007, 4, 1693-1706. (Pubitemid 47381192)
88. Rumsfeld, J.S; Nallamothu, B.K. The hope and fear of rimonabant. J. Am. Med. Assoc., 2008, 299, 1601-1602. (Pubitemid 351482800)
89. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 1998, 284, 644-650. (Pubitemid 28086654)
90. 1 receptor: Importance of the C-3 carboxamide oxygen/lysine 3.28(192) interaction. J. Med. Chem., 2006, 49, 5969-5987. (Pubitemid 44484943)
91. 1 cannabinoid receptor. J. Pharmacol. Exp. Therap., 2003, 306, 363-370. (Pubitemid 36734393)
92. Lange, J.H.M.; Coolen, H.K.A.C.; van Stuivenberg, H.H.; Dijksman, J.A.R.; Herremans, A.H.J.; Ronken, E.; Keizer, H.G.; Tipker, K.; McCreary, A.C.; Veerman, W.; Wals, H.C.; Stork, B.; Verveer, P.C.; Den Hartog, A.P.; De Jong, N.M.J.; Adolfs, T.J.P.; Hoogendoorn, J.; Kruse, C.G. Synthesis, biological properties, and molecular modeling investigations of novel 3,4- diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem., 2004, 47, 627-643. (Pubitemid 38129720)
93. Lin, L.S.; Lanza Jr., T.J.; Jewell, J.P.; Liu, P.; Shah, S.K.; Qi, H.; Tong, X.; Wang, J.; Xu, S.S.; Fong, T.M.; Shen, C.-P.; Lao, J.; Xiao, J.C.; Shearman, L.P.; Stribling, D.S.; Rosko, K.; Strack, A.; Marsh, D.J.; Feng, Y.; Kumar, S.; Samuel, K.; Yin, W.; Van der Ploeg, L.H.-T.; Goulet, M.T.; Hagmann, W.K. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-l]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med. Chem., 2006, 49, 7584-7587. (Pubitemid 46033647)
94. De Petrocellis L.; Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: Focus on Gprotein- coupled receptors and transient receptor potential channels. J. Neuroimmun. Pharmacol., 2010, 5, 103-121.
95. Jacobsson, S.O.; Wallin, T.; Fowler, C.J. Inhibition of Rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exper. Ther., 2001, 299, 951-959. (Pubitemid 33104965)
96. Bisogno, T.; Hanus, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, S.D.E.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 2001, 134, 845-52. (Pubitemid 33016156)
97. De Petrocellis, L.; Vellani, V.; Schiano-Moriello, A.; Marini, P.; Magherini, P.C.; Orlando, P.; Di Marzo, V. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J. Pharmacol. Exp. Ther., 2008, 325, 1007-1015. (Pubitemid 351724325)
98. Cascio, M.G.; Gauson, L.A.; Stevenson, L.A.; Ross, R.A.; Pertwee, R.G. Evidence that the plant cannabinoid cannabigerol is a highly potent 2- adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br. J. Pharmacol., 2010, 159, 129-141.
99. Zanelati, T.V.; Biojone, C.; Moreira, F.A.; Guimaraes, F.S.; Joca, S.R.L. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br. J. Pharmacol., 2010, 159, 122-128.
100. 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw oedema models. Life Sci., 1974, 15, 251-260.
101. 9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-B and interferon-/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem., 2010, 285, 1616-1626.
102. Carrier, E.J.; Auchampach, J.A.; Hillard, C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 7895-7900.
103. Burstein, S.H.; Audette, C.A.; Breuer, A.; Devane, W.A.; Colodner, S.; Doyle, S.A.; Mechoulam, R. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J. Med. Chem., 1992, 35, 3135-3141.
104. Klein, T.W.; Newton, C.A. Therapeutic potential of cannabinoid-based drugs. Adv. Exp. Med. Biol., 2007, 601, 395-413.
105. Wilkinson, J.D.; Williamson, E.M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism, and have a potential therapeutic value in the treatment of psoriasis. J. Dermatol. Sci., 2007, 45, 87-92. (Pubitemid 46108487)
106. Sun, Y.; Alexander, S.P.H.; Garle, M.J.; Gibson, C.L.; Hewitt, K.; Murphy, S.P.; Kendall, D.A.; Bennett, A.J. Cannabinoid activation of PPAR: A novel neuroprotective mechanism. Brit. J. Pharmacol., 2007, 152, 734-743. (Pubitemid 350034991)
107. Russo, E.B.; Burnett, A.; Hall, B.; Parker, K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res., 2005, 30, 1037-43. (Pubitemid 41570039)
108. 9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol., 1999, 55, 8-13. (Pubitemid 29042516)
109. 9- tetrahydrocannabinol against N-methyl-D-aspartate-induced AF5 cell death. Mol. Brain Res., 2005, 134, 215-225.
110. 9- tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 8268-8273. (Pubitemid 28326102)
111. Darlington, C.L. Dexanabinol: A novel cannabinoid with neuroprotective properties. Drugs, 2003, 6, 976-979. (Pubitemid 37321427)
112. Manahan-Vaughan, D.; von Haebler, D.; Winter C.; Juckel, C.; Heinemann, U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus, 2008, 12, 125-134. (Pubitemid 351413480)
113. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernandez- Ruiz, J. Cannabinoids provide neuroprotection against 6- hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson 's disease. Neurobiol. Dis., 2005, 19, 96-107. (Pubitemid 40544727)
114. 9- tetrahydrocannabinol and cannabidiol. Euphytica, 2004, 140, 73-82. (Pubitemid 40473739)
115. Aguado, T.; Carracedo, A.; Julien, B.; Velasco, G.; Milman, G.; Mechoulam, R.; Alvarez, L.; Guzman, M.; Galve-Roperh, I. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J. Biol. Chem., 2007, 282, 6854-6862. (Pubitemid 47100911)
116. 9- tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J. Natl. Canc. Inst., 1976, 56, 655-8.
117. 9- tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res., 2006, 66, 6615-6666.
118. Massi, P.; Vaccani, A.; Bianchessi, S.; Costa, B.; Macchi, P.; Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell. Mol. Life Sci., 2006, 63, 2057-2066. (Pubitemid 44359745)
119. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Therap., 2006, 318, 1375-1387. (Pubitemid 44268348)
120. Wu, H.-Y.; Jan, T.-R. Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion. Toxicol. Lett., 2010, 195, 68-74.
121. Holland, M.L.; Panetta, J.A.; Hoskins, J.M.; Bebawy, M.; Roufogalis, B.D.; Allen, J.D.; Arnold, J.C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol., 2006, 71, 1146-1154. (Pubitemid 43357895)
122. Zhu, H.-J.; Wang, J.-S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B.; Gefroh, H.A.; DeVane, C.L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J. Pharm. Exp. Therap., 2006, 317, 850-857.
123. Holland, M.L.; Lau, D.T.T.; Allen, J.D.; Arnold, J.C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol., 2007, 152, 815-824. (Pubitemid 350034987)
124. Holland, M.L.; Allen, J.D.; Arnold, J.C. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol., 2008, 591, 128-31.
125. Turner, C.E.; Elsohly, M.A. Biological activity of cannabichromene, its homologs and isomers. J. Clin. Pharmacol., 1981, 21, 283S-291S.
126. Elsohly, H.N.; Turner, C.E.; Clark, A.M.; Elsohly, M.A. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J. Pharm. Sci., 1982, 71, 1319-1323. (Pubitemid 13209450)
127. 9- tetrahydrocannabinol and cannabidiol. Lab. Chemother. Natl. Inst. Public Health, 1976, 42, 9-12;
128. Chem. Abstr. 1976, 85, 14622.
129. Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M.M. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J. Nat. Prod., 2008, 71, 1427-1430.